PMID- 28091402
OWN - NLM
STAT- MEDLINE
DCOM- 20170313
LR  - 20181113
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 130
IP  - 2
DP  - 2017 Jan 20
TI  - Geriatric Assessment to Predict Survival and Risk of Serious Adverse Events in 
      Elderly Newly Diagnosed Multiple Myeloma Patients: A Multicenter Study in China.
PG  - 130-134
LID - 10.4103/0366-6999.197977 [doi]
AB  - BACKGROUND: Elderly multiple myeloma (MM) patients often tend to suffer a variety 
      of diseases, so the treatment of choice is very difficult for the elderly myeloma 
      patients. The overall survival (OS) time and side effects with elderly patients 
      are unclear in China. The study tried to find out the role of geriatric 
      assessment in the Chinese elderly MM. METHODS: We retrospectively analyzed the 
      data of 628 newly diagnosed patients from six hospitals from June 2011 to June 
      2013. A geriatric assessment had been performed to assess comorbidities, 
      cognitive, and physical status for these patients. The primary endpoint was to 
      evaluate different physical states of elderly patients with OS time and 
      treatment-related side effects. RESULTS: An additive scoring system (range: 0-5), 
      based on age, Katz's Activity of Daily Living (ADL) and Lawton's Instrumental 
      Activity of Daily Living (IADL) </=5 and Charlson Comorbidity Index (CCI) was 
      developed to identify three groups: fit (score = 0); intermediate-fitness (score 
      = 1); and frail (score >/=2). The 3-year OS was 63% in fit patients, 63% in 
      intermediate-fitness patients, and 49% in frail patients >/=3 hematologic adverse 
      events (AEs) were documented in 45 (35.4%) fit, 34 (34%) intermediate-fitness, 
      and 121 (30.2%) frail patients. The risk of a grade >/=3 hematologic AEs was not 
      significantly increase in intermediate-fitness (hazard ratios [HR]: 0.99, 95% 
      confidence interval [CI]: 0.54-1.47, P = 1.000) and in frail patients (HR: 1.16, 
      95% CI: 0.70-1.93, P = 0.558) compared with fit ones. CONCLUSIONS: MM occurs 
      earlier in life and being advanced when the diagnosis is made in the mainland of 
      China. The overall survival in frailty with International Staging System (ISS) 
      II/III was the worst in all patients.
FAU - Zhong, Yu-Ping
AU  - Zhong YP
AD  - Department of Hematology, Beijing Chaoyang Hospital (West), Capital Medical 
      University, Beijing University Clinical Research Institute, Beijing 100043, 
      China.
FAU - Zhang, Yi-Zhuo
AU  - Zhang YZ
AD  - Department of Hematology, Tianjin Medical University Cancer Institute and 
      Hospital, Tianjin Cancer Hospital, Tianjin 300000, China.
FAU - Liao, Ai-Jun
AU  - Liao AJ
AD  - Department of Hematology, Shengjing Hospital of China Medical University, 
      Shenyang, Liaoning 110004, China.
FAU - Li, Su-Xia
AU  - Li SX
AD  - Department of Hematology, The People's Liberation Army 301 Hospital, Beijing 
      100853, China.
FAU - Tian, Chen
AU  - Tian C
AD  - Department of Hematology, The People's Liberation Army 304 Hospital, Beijing 
      100048, China.
FAU - Lu, Jin
AU  - Lu J
AD  - Department of Hematology, Peking University People's Hospital and Peking 
      University Institute of Hematology, Beijing 100044, China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
SB  - IM
MH  - Activities of Daily Living
MH  - Aged
MH  - China
MH  - Cognition/physiology
MH  - Female
MH  - Geriatric Assessment/*methods
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Multiple Myeloma/*mortality/*physiopathology/psychology
MH  - Retrospective Studies
PMC - PMC5282667
COIS- There are no conflicts of interest.
EDAT- 2017/01/17 06:00
MHDA- 2017/03/14 06:00
PMCR- 2017/01/20
CRDT- 2017/01/17 06:00
PHST- 2017/01/17 06:00 [entrez]
PHST- 2017/01/17 06:00 [pubmed]
PHST- 2017/03/14 06:00 [medline]
PHST- 2017/01/20 00:00 [pmc-release]
AID - ChinMedJ_2017_130_2_130_197977 [pii]
AID - CMJ-130-130 [pii]
AID - 10.4103/0366-6999.197977 [doi]
PST - ppublish
SO  - Chin Med J (Engl). 2017 Jan 20;130(2):130-134. doi: 10.4103/0366-6999.197977.